2016-08-01 14:44:47 UTC

Update on the Safety Profile of Nonselective Beta Blockers

Aug. 2, 2016

CGH meta-analysis finds that NSBBs do not increase mortality in patients with cirrhosis and ascites or refractory ascites.

Nonselective beta blockers (NSBBs) do not significantly increase the risk of death in patients with cirrhosis and ascites or refractory ascites, researchers report in the August issue of Clinical Gastroenterology and Hepatology (CGH). The findings from this meta-analysis do not support the position that NSBBs be routinely withheld from patients with ascites.

The researchers performed a meta-analysis of data from studies of NSBBs to determine whether they are more likely to harm or help patients with cirrhosis. The authors found that use of NSBBs was not associated with increased all-cause mortality. Similar findings were made for patients with nonrefractory ascites or refractory ascites.

Read more about this CGH study on the AGA Journals Blog

More on Cirrhosis

Blog: Special 15th Anniversary Collection from Clinical Gastroenterology and Hepatology

Oct. 11, 2017

Celebrate this milestone with a look back at landmark articles, commentaries and reviews. Read more on the AGA Journals blog.

Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis

Oct. 11, 2017

Statin use is probably associated with lower risk of hepatic decompensation and mortality, and might reduce portal hypertension, in patients with CLDs.

Cirrhosis Presenting as Cutaneous Calciphylaxis

Oct. 11, 2017

A 73-year-old woman with a history of hypertension presented with a 3-month history of a painful, non-healing right calf ulcer and 2–3 weeks of painful, dusky purple patches on the right thigh.